These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 35027218)

  • 21. A novel large intragenic DPYD deletion causing dihydropyrimidine dehydrogenase deficiency: a case report.
    Malekkou A; Tomazou M; Mavrikiou G; Dionysiou M; Georgiou T; Papaevripidou I; Alexandrou A; Sismani C; Drousiotou A; Grafakou O; Petrou PP
    BMC Med Genomics; 2024 Mar; 17(1):78. PubMed ID: 38528593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy.
    van Kuilenburg AB; Häusler P; Schalhorn A; Tanck MW; Proost JH; Terborg C; Behnke D; Schwabe W; Jabschinsky K; Maring JG
    Clin Pharmacokinet; 2012 Mar; 51(3):163-74. PubMed ID: 22339448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.
    Meulendijks D; Henricks LM; Sonke GS; Deenen MJ; Froehlich TK; Amstutz U; Largiadèr CR; Jennings BA; Marinaki AM; Sanderson JD; Kleibl Z; Kleiblova P; Schwab M; Zanger UM; Palles C; Tomlinson I; Gross E; van Kuilenburg AB; Punt CJ; Koopman M; Beijnen JH; Cats A; Schellens JH
    Lancet Oncol; 2015 Dec; 16(16):1639-50. PubMed ID: 26603945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.
    Lunenburg CATC; Henricks LM; Guchelaar HJ; Swen JJ; Deenen MJ; Schellens JHM; Gelderblom H
    Eur J Cancer; 2016 Feb; 54():40-48. PubMed ID: 26716401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unveiling Discrepant and Rare Dihydropyrimidine Dehydrogenase (DPYD) Results Using an In-House Genotyping Test: A Case Series.
    Nguyen DG; Morris SA; Chen A; Moore DC; Hanson SL; Larck C; Musselwhite LW; Turner JD; Salem ME; Kwange SO; Hamilton A; Steuerwald N; Patel JN
    J Natl Compr Canc Netw; 2024 May; 22(4):. PubMed ID: 38754463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survey of US Medical Oncologists' Practices and Beliefs Regarding
    Koo K; Pasternak AL; Henry NL; Sahai V; Hertz DL
    JCO Oncol Pract; 2022 Jun; 18(6):e958-e965. PubMed ID: 35239419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study.
    de With M; Knikman J; de Man FM; Lunenburg CATC; Henricks LM; van Kuilenburg ABP; Maring JG; van Staveren MC; de Vries N; Rosing H; Beijnen JH; Pluim D; Modak A; Imholz ALT; van Schaik RHN; Schellens JHM; Gelderblom H; Cats A; Guchelaar HJ; Mathijssen RHJ; Swen JJ; Meulendijks D
    Clin Pharmacol Ther; 2022 Jul; 112(1):62-68. PubMed ID: 35397172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients.
    Stavraka C; Pouptsis A; Okonta L; DeSouza K; Charlton P; Kapiris M; Marinaki A; Karapanagiotou E; Papadatos-Pastos D; Mansi J
    Breast Cancer Res Treat; 2019 Jun; 175(2):511-517. PubMed ID: 30746637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists].
    Loriot MA; Masskouri F; Carni P; Le Malicot K; Seitz JF; Michel P; Legoux JL; Bouché O; André T; Faroux R; Delaloge S; Malka D; Guigay J; Thariat J; Thomas F; Barin-Le-Guellec C; Ciccolini J; Boyer JC; Étienne-Grimaldi MC
    Bull Cancer; 2019 Sep; 106(9):759-775. PubMed ID: 31253356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe.
    de With M; Sadlon A; Cecchin E; Haufroid V; Thomas F; Joerger M; van Schaik RHN; Mathijssen RHJ; Largiadèr CR;
    ESMO Open; 2023 Apr; 8(2):101197. PubMed ID: 36989883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tolerance-based capecitabine dose escalation after DPYD genotype-guided dosing in heterozygote DPYD variant carriers: a single-center observational study.
    Kleinjan JP; Brinkman I; Bakema R; van Zanden JJ; van Rooijen JM
    Anticancer Drugs; 2019 Apr; 30(4):410-415. PubMed ID: 30628914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping.
    White C; Scott RJ; Paul C; Ziolkowski A; Mossman D; Fox SB; Michael M; Ackland S
    Clin Pharmacol Ther; 2022 Oct; 112(4):791-802. PubMed ID: 35607723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Prevalence of DPYD*9A(c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis.
    Maharjan AS; McMillin GA; Patel GK; Awan S; Taylor WR; Pai S; Frankel AE; Nelson C; Wang B; Hosein PJ; Singh AP; Khushman M
    Clin Colorectal Cancer; 2019 Sep; 18(3):e280-e286. PubMed ID: 31160238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score.
    Henricks LM; Lunenburg CA; Meulendijks D; Gelderblom H; Cats A; Swen JJ; Schellens JH; Guchelaar HJ
    Pharmacogenomics; 2015; 16(11):1277-86. PubMed ID: 26265346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Dihydropyrimidine dehydrogenase deficiency and toxicity to fluoropyrimidine].
    Boisdron-Celle M; Morel A; Gamelin E
    Ann Biol Clin (Paris); 2010; 68(1):27-32. PubMed ID: 20146975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-World Impact of an In-House Dihydropyrimidine Dehydrogenase (
    Nguyen DG; Morris SA; Hamilton A; Kwange SO; Steuerwald N; Symanowski J; Moore DC; Hanson S; Mroz K; Lopes KE; Larck C; Musselwhite L; Kadakia KC; Koya B; Chai S; Osei-Boateng K; Kalapurakal S; Swift K; Hwang J; Patel JN
    JCO Precis Oncol; 2024 Jun; 8():e2300623. PubMed ID: 38935897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implementation and clinical benefit of DPYD genotyping in a Danish cancer population.
    Paulsen NH; Pfeiffer P; Ewertz M; Fruekilde PBN; Feddersen S; Holm HS; Bergmann TK; Qvortrup C; Damkier P
    ESMO Open; 2023 Feb; 8(1):100782. PubMed ID: 36791638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity.
    Yang CG; Ciccolini J; Blesius A; Dahan L; Bagarry-Liegey D; Brunet C; Varoquaux A; Frances N; Marouani H; Giovanni A; Ferri-Dessens RM; Chefrour M; Favre R; Duffaud F; Seitz JF; Zanaret M; Lacarelle B; Mercier C
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):49-56. PubMed ID: 20204365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?
    Meulendijks D; Cats A; Beijnen JH; Schellens JH
    Cancer Treat Rev; 2016 Nov; 50():23-34. PubMed ID: 27589829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio.
    Thomas F; Hennebelle I; Delmas C; Lochon I; Dhelens C; Garnier Tixidre C; Bonadona A; Penel N; Goncalves A; Delord JP; Toulas C; Chatelut E
    Clin Pharmacol Ther; 2016 Feb; 99(2):235-42. PubMed ID: 26265035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.